Ana Fortuna graduated in Pharmaceutical Sciences at the Faculty of Pharmacy of University of Coimbra, in 2006. In the same year, she got a FCT PhD fellowship with the project entitled “Análise farmacométrica de derivados da carbamazepina: avaliação in vitro, in vivo e in silico das suas propriedades farmacológicas“, which was awarded, in 2012, by Liga Portuguesa contra a Epilepsia.
In 2011, Ana Fortuna achieved the PhD degree in Pharmacology at the Faculty of Pharmacy of University of Coimbra and continued her research work as a member of Pharmacometrics Group from Centre for Neurosciences and Cell Biology, University of Coimbra (Coimbra), Portugal.
Since 2012, Ana Fortuna is Auxiliary Professor at Faculty of Pharmacy of the University of Coimbra. As a researcher, she develops new in vitro/in silico models and performes in vivo studies to characterize drug pharmacokinetics and new bioanalytical methods to quantify drugs and metabolites in several biological matrices. Furthermore she is investigating the potential of intranasal administration of anti-epileptic drugs, a work awarded in 2015 by Liga Portuguesa contra a Epilepsia.
Ana Fortuna is author and co-author of more than 50 international articles and author of two chapter books and co-author of other two chapters.
Her areas of research include:
- Development, validation and employment of in vitro techniques to:
• estimate drugs permeability through intestinal mucosa and blood-brain barrier,
• estimate drugs plasma protein binding,
• identify substrates of efflux transporters (e.g. P-glycoprotein, breast cancer receptor protein);
• characterize the metabolism of new chemical entities.
- In vitro and in vivo preclinical pharmacokinetic evaluation of antiepileptic drugs, COMP inhibitors, and antimicrobial drugs;
- Investigation intranasal administration potential to delivery drugs into the brain or bloodstream in comparison to the most common routes (oral, IV, IP).
- Development and full validation of bioanalytical methodologies to quantify drugs and metabolites in biological samples by HPLC. This is being employed in clinical quotidiane of therapeutic drug monitoring.